Exsilio Therapeutics Emerges With $82M

The funding was co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight. Exsilio was seed-funded by OrbiMed.

Exsilio Therapeutics is developing genomic medicines that can be delivered in lipid nanoparticles to durably and safely treat a broad range of diseases, including genetic diseases, cancer, and autoimmune conditions. Exsilio’s technology is based on naturally occurring genetic elements that can precisely insert new genes into a cell through RNA intermediate templates. Exsilio uses predictive in silico modeling and wet lab-based experimentation to engineer such elements for precise insertion of therapeutic genes into safe harbor sites of disease-relevant cells. Because Exsilio’s medicines are encoded in mRNA, they can be delivered using validated, non-viral delivery platforms that are safe, efficient, scalable, and cost-effective, and that allow redosing to effect with a curative intent.

(c) by Massinvestor, Inc. For contact info, please check out our about page.